Autologous stem cell transplantation in refractory Crohn’s disease – low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study
James O. Lindsay(Barts Health NHS Trust), C J Hawkey(NIHR Nottingham Digestive Diseases Biomedical Research Unit), Emmanuelle Polge(Inserm), John A. Snowden(Sheffield Teaching Hospitals NHS Foundation Trust), Lizzie Swaby(King's College London), Myriam Labopin(Sorbonne Université), Jack Satsangi(Western General Hospital), Richard Emsley(University of Manchester), A. Graham Pockley(Royal Hallamshire Hospital), Daniel Hind(University of Sheffield), Diana Papaioannou(University of Sheffield), Alan Lobo(Sheffield Teaching Hospitals NHS Foundation Trust), Manuela Badoglio(Sorbonne Université), Miles Parkes(Cambridge University Hospitals NHS Foundation Trust), John G. Gribben(Queen Mary University of London), Simon Travis(University of Oxford), Laura Mandefield(University of York), Gemma A. Foulds(John Radcliffe Hospital), Katie Mellor(University of Sheffield), Ellen Lee(Ford Motor Company (United States))
Cited by 30
Related Papers
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
|Nature Genetics|2015|2.8k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease
|Nature Genetics|2017|1.5k